Komal Jhaveri, Medical Oncologist and Clinical Researcher of Breast Medicine and Early Drug Development, Section Head of Endocrine Therapy, Breast Medicine Service, and Clinical Director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared a post by Stephen Dunn, Executive Director, Head of MENA, Medscape Education, on LinkedIn, adding:
“The treatment algorithm is dynamically evolving with multiple new data sets that were just presented at ASCO, ESMO and will be presented at SABCS in less than 2 weeks. Join us as we put these data into context and discuss what our treatment paradigm will look like for ER POs HER2 – MBC.”
Quoting Stephen Dunn‘s post:
“Essential Education for Oncology Professionals!
Don’t miss this critical 30-minute webinar on the evolving landscape of ER-positive/HER2-negative metastatic breast cancer (MBC) management.
Join leading experts Komal Jhaveri, MD FACP, FASCO (Memorial Sloan Kettering Cancer Center, US) and Dr. Shaheenah Dawood (Mediclinic Hospital, Dubai, UAE) as they analyze the latest clinical data on Current and Future Oral SERD Strategies.
This program is vital for medical oncologists, PAs, NPs, and pharmacists involved in breast cancer care. Stay ahead of the curve on new treatment algorithms and data surrounding oral Selective Estrogen Receptor Degraders (SERDs).
When: Monday, December 15, 2025 | 11:30 AM – 12:00 PM ET.”
More posts featuring Komal Jhaveri on OncoDaily.